Regeneron Pharmaceuticals
REGNRegeneron Pharmaceuticals is a premier biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company has built a diversified portfolio of FDA-approved treatments and maintains a robust pipeline across oncology, immunology, ophthalmology, and other therapeutic areas. Regeneron's proprietary VelociSuite technologies, including VelocImmune mice and advanced manufacturing capabilities, enable rapid drug discovery and development. With multiple billion-dollar commercial products and strong financial performance, Regeneron ranks among the most successful biotech companies globally.
REGN · Stock Price
Historical price data
AI Company Overview
Regeneron Pharmaceuticals is a premier biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company has built a diversified portfolio of FDA-approved treatments and maintains a robust pipeline across oncology, immunology, ophthalmology, and other therapeutic areas. Regeneron's proprietary VelociSuite technologies, including VelocImmune mice and advanced manufacturing capabilities, enable rapid drug discovery and development. With multiple billion-dollar commercial products and strong financial performance, Regeneron ranks among the most successful biotech companies globally.
Technology Platform
Regeneron's proprietary VelociSuite technologies include VelocImmune for generating fully human antibodies, VelociGene for genetic engineering, and advanced biomanufacturing capabilities. These integrated platforms enable rapid drug discovery and development across multiple therapeutic areas.
Pipeline
453| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Intravitreal Aflibercept Injection 2mg | Neovascular Age-related Macular Degeneration | Approved | |
| Intravitreal aflibercept injection 2.0mg | Polypoidal Choroidal Vasculopathy | Approved | |
| Pozelimab | CHAPLE Disease | Approved | |
| Dupilumab | Atopic Dermatitis | Approved | |
| Aflibercept | Age Related Macular Degeneration | Approved |
Funding History
1FDA Approved Drugs
9Opportunities
Risk Factors
Competitive Landscape
Regeneron competes with major pharmaceutical companies like Roche/Genentech, Novartis, AbbVie, and Bristol Myers Squibb across its key therapeutic areas. The company differentiates itself through its integrated drug discovery and development platform, proprietary technologies, and focus on developing best-in-class therapies with strong clinical profiles.